CD274 and neoplasm: Zymeworks recently introduced a PROTECT (PROgrammed Tumor Engagement & Checkpoint/Costimulation Targeting) platform, an innovative technology designed to deliver multifunctional tumor-specific activity while simultaneously enhancing immune modulation through the conditional activity of a natural immunomodulatory pair such as PD-1/PD-L1.